To determine if the compounds were active PKD1 inhibitors in cells, we determined their ability to inhibit phorbol 12-myristate 13-acetate (PMA)-induced activation of PKD1 in LNCaP prostate cancer cells. Here, PKD1 is linked to prostate cancer.